Erasca (NASDAQ:ERAS - Get Free Report)'s stock had its "overweight" rating restated by investment analysts at Morgan Stanley in a research report issued on Friday,Benzinga reports. They presently have a $4.00 price target on the stock. Morgan Stanley's price target indicates a potential upside of 159.74% from the stock's current price.
Several other brokerages also recently issued reports on ERAS. Jefferies Financial Group started coverage on shares of Erasca in a report on Monday, November 18th. They set a "buy" rating and a $6.00 price target for the company. Bank of America upgraded shares of Erasca from a "neutral" rating to a "buy" rating and set a $5.00 target price for the company in a research note on Tuesday, January 7th. Finally, HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Erasca in a research report on Wednesday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Erasca presently has an average rating of "Buy" and an average price target of $5.42.
Check Out Our Latest Analysis on ERAS
Erasca Stock Up 7.7 %
Erasca stock traded up $0.11 during mid-day trading on Friday, hitting $1.54. 1,631,042 shares of the company were exchanged, compared to its average volume of 1,678,325. Erasca has a 1-year low of $1.23 and a 1-year high of $3.45. The business has a fifty day moving average of $1.82 and a 200 day moving average of $2.44. The company has a market capitalization of $435.40 million, a PE ratio of -1.86 and a beta of 1.22.
Institutional Trading of Erasca
Hedge funds and other institutional investors have recently modified their holdings of the stock. AXQ Capital LP bought a new position in Erasca in the 4th quarter valued at $27,000. Mackenzie Financial Corp bought a new stake in shares of Erasca during the fourth quarter worth $28,000. Neuberger Berman Group LLC acquired a new position in shares of Erasca during the fourth quarter valued at $33,000. Brevan Howard Capital Management LP bought a new position in Erasca in the fourth quarter valued at about $41,000. Finally, Cibc World Markets Corp acquired a new stake in Erasca in the fourth quarter worth about $43,000. Institutional investors and hedge funds own 67.78% of the company's stock.
About Erasca
(
Get Free Report)
Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.
See Also
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
